BHVN241220P37500
- 1.10
- -0.50-31.25%
Biohaven Newsroom
BTIG Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $59
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $69
Jefferies Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $64
Jefferies Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $58 to $76
Biohaven Ltd.: Buy Rating Affirmed Amid Promising Drug Prospects and Strategic FDA Engagement
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Vigil Neuroscience Inc (VIGL) and Biohaven Ltd. (BHVN)
Biohaven Is Maintained at Outperform by RBC Capital
Promising Potential of Biohaven's Taldefgrobep Alfa in Obesity Treatment and Niche SMA Market Justifies Buy Rating
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro
RBC Cuts Price Target on Biohaven to $58 From $66, Maintains Outperform Rating
Express News | Scholar Rock Holding Shares Jump 37.5% After Rival Biohaven's Rare Genetic Disorder Drug Fails Trial Goal
Sector Update: Health Care Stocks Edge Higher Premarket Monday
Biohaven's Spinal Muscular Atrophy Treatment Fails Primary Goal in Study; Plans Treatment for Obesity
Biohaven Says Potential Neurodegenerative Disease Treatment Failed to Achieve Statistical Significance; Shares Fall Pre-Bell
Biohaven Pharma Falls 13% Following Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
Express News | Biohaven Shares Fall 12.3% Premarket as Sma Treatment Did Not Show Statistically Significant Difference on Primary Outcome in Trial
Biohaven Says In RESILIENT SMA Study, Taldefgrobep Alfa Showed Clinically Meaningful Improvements In Motor Function At All Timepoints On The Motor Function Measurement-32 Scale, But The Treatment Arm Did Not Statistically Separate On The Primary...
Express News | Biohaven Ltd - Taldefgrobep Well-Tolerated With No Treatment-Related Saes